Generally, inflammatory markers, such as NLR, PLR, LMR, and CRP, were reported their associations with cancer cachexia [23–25], and some previous reports demonstrated that the elevations of these inflammatory markers were associated with poor outcome of cancer patients treated with ICIs therapy [26–29]. The gene discussed is CRP; the disease is cancer.